2. Search Result
Search Result
Results for "

et1

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

14

Peptides

1

Inhibitory Antibodies

8

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0202
    Endothelin 1 (swine, human)
    Maximum Cited Publications
    8 Publications Verification

    et-1 (swine, human)

    		 Endothelin Receptor Metabolic Disease Inflammation/Immunology
    Endothelin 1 (swine, human) (ET-1) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB [1].
    Endothelin 1 (swine, human)
  • HY-113046
    5-Methyltetrahydrofolic acid
    5+ Cited Publications

    5-Methyl THF; 5-MTHF

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases [1] .
    5-Methyltetrahydrofolic acid
  • HY-15894A
    BQ-788
    Maximum Cited Publications
    13 Publications Verification

    		 Endothelin Receptor Cardiovascular Disease Endocrinology Cancer
    BQ-788 is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM [1].
    BQ-788
  • HY-B1100
    Estradiol cypionate
    Maximum Cited Publications
    11 Publications Verification

    		 Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    Estradiol cypionate is the 17β-cypionate ester of Estradiol, which inhibits ET-1 synthesis by acting on estrogen receptors [1].
    Estradiol cypionate
  • HY-15894
    BQ-788 sodium salt
    Maximum Cited Publications
    13 Publications Verification

    		 Endothelin Receptor Cardiovascular Disease Endocrinology Cancer
    BQ-788 sodium salt is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells [1].
    BQ-788 sodium salt
  • HY-P4159
    Endothelin-1 (1-31) (Human)
    1 Publications Verification

    		 ERK Cardiovascular Disease
    Endothelin-1 (1-31) (Human) is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) is derived from the selective hydrolysis of big ET-1 by chymase [1].
    Endothelin-1 (1-31) (Human)
  • HY-N2575
    Hypocrellin A
    2 Publications Verification

    		 PKC Bacterial Parasite HIV VSV VEGFR Bcl-2 Family Apoptosis Infection Metabolic Disease Cancer
    Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml) [1] .
    Hypocrellin A
  • HY-N7543
    Schisantherin D

    		HIV Endothelin Receptor Infection Metabolic Disease
    Schisantherin D is a lignan. Schisantherin D can be isolated from Kadsura interior. Schisantherin D downregulates the expression of ETBR and inhibits the secretion of ECM and ET-1. Schisantherin D alleviates EtOH + ET-1-induced hepatocyte cytotoxicity. Schisantherin D potently inhibits HIV replication in cells [1] .
    Schisantherin D
  • HY-118060
    Dipeptide 2

    N-Valyltryptophan; Val-Trp

    		 Angiotensin-converting Enzyme (ACE) Calcium Channel NO Synthase Cardiovascular Disease
    Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC50 of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats [1].
    Dipeptide 2
  • HY-114367
    Delphinidin 3-rutinoside chloride
    1 Publications Verification

    Delphinidin 3-O-rutinoside chloride

    		 Endothelin Receptor NO Synthase Myosin GLP Receptor Neurological Disease Metabolic Disease
    Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes [1] .
    Delphinidin 3-rutinoside chloride
  • HY-P0202A
    Endothelin 1 (swine, human) TFA
    Maximum Cited Publications
    8 Publications Verification

    et-1 (swine, human) TFA

    		 Endothelin Receptor Cardiovascular Disease
    Endothelin 1 (swine, human) (ET-1) TFA is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 TFA acts through two types of receptors ETA and ETB [1].
    Endothelin 1 (swine, human) TFA
  • HY-P4159A
    Endothelin-1 (1-31) (Human) TFA
    1 Publications Verification

    		 ERK Cardiovascular Disease
    Endothelin-1 (1-31) (Human) TFA is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) TFA is derived from the selective hydrolysis of big ET-1 by chymase [1].
    Endothelin-1 (1-31) (Human) TFA
  • HY-17352
    Clazosentan

    Ro 61-1790; VML 588; AXV-034343

    		 Endothelin Receptor Cardiovascular Disease
    Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction [1] .
    Clazosentan
  • HY-120295
    A-192621
    2 Publications Verification

    		 Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology
    A-192621, a chemical probe, is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level [1] .
    A-192621
  • HY-15195
    Avosentan

    Ro 67-0565; SPP-301

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure [1] .
    Avosentan
  • HY-P2538
    Big Endothelin-1 (1-38), human

    		Vasopressin Receptor Cardiovascular Disease
    Big Endothelin-1 (1-38), human is the precursor of endothelin-1. Endothelin-1 (ET-1) is a potent vasopressor peptide [1].
    Big Endothelin-1 (1-38), human
  • HY-P4641
    H-Trp-Phe-OH

    Trp-Phe

    		 Angiotensin-converting Enzyme (ACE) Endothelin Receptor Cardiovascular Disease
    H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis [1].
    H-Trp-Phe-OH
  • HY-P1016B
    BQ-3020 ammonium

    		Endothelin Receptor Cardiovascular Disease
    BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research [1] . .
    BQ-3020 ammonium
  • HY-19529
    Ro 46-2005

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.
    Ro 46-2005
  • HY-113046S1
    5-Methyltetrahydrofolic acid-13C6

    5-Methyl THF-13C6; 5-MTHF-13C6

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    5-Methyltetrahydrofolic acid- 13C6 (5-Methyl THF- 13C6) is 13C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases [1] .
    5-Methyltetrahydrofolic acid-13C6
  • HY-P3733
    Big Endothelin-1 (22-38), human

    		Endothelin Receptor Cardiovascular Disease
    Big Endothelin-1 (22-38), human is derived from human, is the 22-38 fragment of Big Endothelin-1 (ET-1) (1-38). Big ET-1 (1-38) is a propeptide of ET-1, which has potent and long-lasting vasoconstrictor effects, equips a specific enzymatic cleavage of the 38 amino acid chain to form ET-1 (1-21) and the C-terminal fragment Big ET-1 (22-38) [1].
    Big Endothelin-1 (22-38), human
  • HY-19890
    Aminaftone

    Aminaftone; Aminaphthone

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 (ET-1) production in vitro by interfering with the transcription of the pre-pro-ET-1 gene.
    Aminaftone
  • HY-RS04162
    EDN1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    EDN1 Human Pre-designed siRNA Set A contains three designed siRNAs for EDN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EDN1 Human Pre-designed siRNA Set A
    EDN1 Human Pre-designed siRNA Set A
  • HY-P1016
    BQ-3020

    		Endothelin Receptor Cardiovascular Disease
    BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
    BQ-3020
  • HY-134013
    Piperitenone oxide

    		DNA/RNA Synthesis Endothelin Receptor Cardiovascular Disease Cancer
    Piperitenone oxide is an orally active monoterpene ketone. Piperitenone oxide can be isolated from the essential oils of plants belonging to Mentha x villosa and Ziziphora clinopodioides. Piperitenone oxide induces differentiation. Piperitenone oxide induces chromosome breakage damage, aneuploidy damage and DNA single-strand breaks. Piperitenone oxide reduces ET-1 levels. Piperitenone oxide exerts antihypertensive effects. Piperitenone oxide can be used in studies related to colon cancer [1] .
    Piperitenone oxide
  • HY-133829
    Zofenoprilat

    		Angiotensin-converting Enzyme (ACE) NO Synthase Reactive Oxygen Species (ROS) Cardiovascular Disease
    Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure [1] .
    Zofenoprilat
  • HY-P4159B
    Endothelin-1 (1-31) (Human) acetate

    		ERK Cardiovascular Disease
    Endothelin-1 (1-31) (Human) acetate is a potent vasoconstrictor and hypertensive agent. Endothelin-1 (1-31) (Human) acetate is derived from the selective hydrolysis of big ET-1 by chymase [1].
    Endothelin-1 (1-31) (Human) acetate
  • HY-B1100R
    Estradiol cypionate (Standard)

    		Reference Standards Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    Estradiol cypionate (Standard) is the analytical standard of Estradiol cypionate. This product is intended for research and analytical applications. Estradiol cypionate is the 17β-cypionate ester of Estradiol, which inhibits ET-1 synthesis by acting on estrogen receptors [1].
    Estradiol cypionate (Standard)
  • HY-112079
    NPC-15669

    		Integrin Cardiovascular Disease
    NPC-15669 is a novel Mac-1 inhibitor. NPC-15669 reduces plasma levels of ET-1, TxB, prostacyclin, AT-III, and total protein S. NPC-15669 can be used in the research of myocardial infarction [1].
    NPC-15669
  • HY-124234
    TA-0201

    		Endothelin Receptor Cardiovascular Disease
    TA-0201 is a novel orally active, competitive, non-peptide endothelin receptor antagonist. TA-0201 antagonizes the specific binding of [ 125I]ET-1 to cloned human receptors of ETA and ETB with Ki values of 15 pM and 41 nM, respectively. TA-0201 inhibits the pressor response to the exogenous big ET-1 [1].
    TA-0201
  • HY-119843
    Asterric Acid

    Dimethylosoic acid; RES-1214-1; TAN 1415A

    		 Antibiotic Infection
    Asterric acid is an antibiotic fungal metabolite that completely inhibits the binding of the potent vasoconstrictor endothelin (ET)-1 to the ETA receptor in A10 cells at 0.1 μM.1 Asterric acid derivatives have also been shown to inhibit VEGF-induced tube formation of human umbilical vein endothelial cells at 3-10 μM, which suggests its usefulness as an antiangiogenic agent.
    Asterric Acid
  • HY-10383
    J-104132

    		Endothelin Receptor Cardiovascular Disease Metabolic Disease
    J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications [1][3].
    J-104132
  • HY-19210
    SB-209670

    		Endothelin Receptor Cardiovascular Disease
    SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty [1].
    SB-209670
  • HY-N5170
    Aselacin A

    		Endothelin Receptor Cardiovascular Disease
    Aselacin A targets endothelin-1 receptor (ET-1 receptor), inhibits the the binding of ET-1 to ETA receptor and ETB receptor. Aselacin A inhibits the ET-1 binding to bovine atrial membrane and porcine cerebral membrane with IC50 of 22 μg/mL and 20 μg/mL. Aselacin A can be used for research of cardiovascular diseases [1].
    Aselacin A
  • HY-120843
    WS009A

    		Endothelin Receptor Cardiovascular Disease
    WS009A is an antagonist for endothelin receptor (ET Receptor) with IC50 of 5.8 and 6.9 μM for ET-1 receptor and ET-2 receptor. WS009A can be used in research of cardiovascular diseases [1].
    WS009A
  • HY-P2539
    Big Endothelin-1 (1-39), porcine

    		Vasopressin Receptor Cardiovascular Disease
    Big Endothelin-1 (1-39), porcine is the precursor of endothelin-1. Endothelin-1 (ET-1) is a potent vasopressor peptide. Big Endothelin-1 (1-39), porcine has similar pressor effects in vivo [1].
    Big Endothelin-1 (1-39), porcine
  • HY-117634
    WS009B

    		Endothelin Receptor Cardiovascular Disease
    WS009B is a selective endothelin receptor antagonist (ET-1: IC50=0.67 μM; ET-2: IC50=0.8 μM). WS009B can be used in the study of cardiovascular diseases [1].
    WS009B
  • HY-P10135
    RES-701-1

    		Endothelin Receptor Cardiovascular Disease
    RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM [1] .
    RES-701-1
  • HY-117814
    BMS-187308

    		Endothelin Receptor Cardiovascular Disease
    BMS-187308 is an orally active endothelin-A (ETA) antagonist, with Kis of 4.7 nM for ETA and 1.7 μM for ETB. BMS-187308 inhibits the pressor response to ET-1 (ED25: 1.2 µmol/kg; iv). BMS-187308 is a suitable tool for investigating the role of endothelin [1].
    BMS-187308
  • HY-17352A
    Clazosentan disodium

    Ro 61-1790 disodium; VML 588 disodium; AXV-034343 disodium

    		 Endothelin Receptor Cardiovascular Disease
    Clazosentan disodium (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan disodium inhibits ET-1-mediated vasoconstriction. Clazosentan disodium prevents cerebral vasospasm, vasospasm-related cerebral infarction [1] .
    Clazosentan disodium
  • HY-149352
    DG1

    		Thymidylate Synthase Cancer
    DG1 (Compound 8Nc) is a Thymidylate Synthase (TS) inhibitor that affects cancer angiogenesis and metabolic reprogramming in NSCLC cells. DG1 can effectively inhibit the expression of CD26, ET-1, FGF-1 and EGF. DG1 also effectively inhibits the proliferation of cancer tissue in the A549 xenograft mouse model [1].
    DG1
  • HY-17352R
    Clazosentan (Standard)

    Ro 61-1790 (Standard); VML 588 (Standard); AXV-034343 (Standard)

    		 Endothelin Receptor Reference Standards Cardiovascular Disease
    Clazosentan (Standard) is the analytical standard of Clazosentan. This product is intended for research and analytical applications. Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction [1] .
    Clazosentan (Standard)
  • HY-106337
    SB 247083

    		Endothelin Receptor Cardiovascular Disease
    SB 247083 is a selective, competitive and orally active endothelin-A receptor antagonist with a Ki of 0.41 nM. SB 247083 shows a Ki of 467 nM to endothelin-B receptor. SB 247083 shows a Kb of 3.5 nM for ET-1-induced contraction of rat aorta. SB 247083 can be used for the research of cardiovascular disease [1].
    SB 247083
  • HY-18211
    CGS 35601

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    CGS 35601 is the inhibitor for endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), with IC50s of 55, 2, and 22 nM, respectively. CGS 35601 suppresses the big endothelin-1 (big ET-1)- and angiotensin I-induced pressor response, and enhances circulation of atrial natriuretic peptide (ANP), regulates the cardiovascular function in SD rats [1].
    CGS 35601
  • HY-N2575R
    Hypocrellin A (Standard)

    		Reference Standards PKC Bacterial Parasite HIV VSV VEGFR Bcl-2 Family Apoptosis Infection Metabolic Disease Cancer
    Hypocrellin A (Standard) is the analytical standard of Hypocrellin A. This product is intended for research and analytical applications. Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml)[1][2][3][4][5][6][7][8][9].
    Hypocrellin A (Standard)
  • HY-13692
    1α-Hydroxyvitamin D5

    CARD-024

    		 Myosin FAK Interleukin Related COX Inflammation/Immunology
    1α-Hydroxyvitamin D5 (CARD-024) is a vitamin D analog with extremely low hypercalcemic effects. 1α-Hydroxyvitamin D5 effectively attenuates the pro-fibrotic response of colonic myofibroblasts to TGFβ and high-stiffness substrates by inhibiting the expression of αSMA, the phosphorylation of FAK, and the gene expression of MLCK and ET-1, while activating the anti-inflammatory pathway of IL-1β/COX-2. 1α-Hydroxyvitamin D5 can be used in research related to intestinal fibrosis associated with Crohn's disease [1].
    1α-Hydroxyvitamin D5
  • HY-15195R
    Avosentan (Standard)

    Ro 67-0565 (Standard); SPP-301 (Standard)

    		 Reference Standards Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
    Avosentan (Standard)
  • HY-113589
    ICI 198615

    		Lipoxygenase Inflammation/Immunology
    ICI 198615 is a lipoxygenase inhibitor. ICI 198615 inhibits the activity of lipoxygenases involved in eicosanoid metabolism. ICI 198615 attenuates the early phase of bronchoconstriction induced by ET-1 [1].
    ICI 198615
  • HY-RS04163
    Edn1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Edn1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Edn1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Edn1 Rat Pre-designed siRNA Set A
    Edn1 Rat Pre-designed siRNA Set A
  • HY-118294
    15-OH Tafluprost

    16-Phenoxy tetranor prostaglandin F2α isopropyl ester; 16-Phenoxy tetranor PGF2α isopropyl ester

    		 Prostaglandin Receptor Cardiovascular Disease
    15-OH Tafluprost, a prostaglandin F2a (PGF2a) analog, relieves endothelin-1 (ET-1)-induced optic nerve head (ONH) blood flow impairment and ET-1-induced contraction of isolated ciliary artery segments [1].
    15-OH Tafluprost

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: